Virtu Financial LLC purchased a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the first quarter of the year, acquiring 7,986 shares valued at approximately $931,000, as reported in its most recent 13F filing with the Securities and Exchange Commission. Axsome Therapeutics reported a quarterly revenue of $150.04 million, exceeding analysts' expectations of $140.02 million, and its earnings per share (EPS) of ($0.92) surpassed the consensus estimate of ($1.00). Several analysts have recently upgraded their ratings for Axsome Therapeutics, with target prices ranging from $150.00 to $190.00, indicating a generally positive outlook. Key institutional investors also adjusted their positions: Principal Financial Group Inc. increased its stake by 42.8%, now owning 295,671 shares worth $34,484,000; Penserra Capital Management LLC acquired a new stake worth $2,229,000; UBS AM increased its position by 20.8%, now owning 57,642 shares worth $4,877,000; Trek Financial LLC acquired a new stake worth $3,446,000; and Edgestream Partners L.P. acquired a new stake worth $8,174,000. Hedge funds and other institutional investors collectively own 81.49% of the company's stock. Analyst ratings include a 'strong-buy' from Cantor Fitzgerald, 'outperform' and price targets from Robert W. Baird, Royal Bank of Canada, Morgan Stanley, and Wells Fargo & Company. The current average rating is 'Buy' with a consensus target price of $178.00. The stock traded up $4.16 to $109.39 on Wednesday, with a 50-day moving average of $105.71 and a 200-day moving average of $110.86. Axsome Therapeutics has a market cap of $5.46 billion, a negative P/E ratio of -21.58, and a beta of 0.51. The company's fifty-two week range is $75.56 to $139.13, with a debt-to-equity ratio of 1.66, quick ratio of 1.51, and current ratio of 1.57. The company reported a negative return on equity of 283.22% and a negative net margin of 49.88%. Research analysts predict a projected EPS of -2.79 for the current year. Insider activity includes COO Mark L. Jacobson selling 25,000 shares at $110.44 for $2,761,000, reducing his ownership by 81.21%, and a director selling 3,750 shares at $105.47 for $395,512.50, reducing their position by 6.93%. Over the last ninety days, insiders sold 93,437 shares valued at $9,834,215, representing 22.30% of the stock. Axsome Therapeutics is a biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, with commercial products including Auvelity (dextromethorphan-bupropion) for major depressive disorder and Sunosi (solriamfetol) for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea.

Virtu Financial LLC Purchases Shares of 7,986 Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Virtu Financial LLC acquired 7,986 shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the first quarter of 2025, valuing the stake at approximately $931,000, as disclosed in its 13F filing with the SEC. Axsome reported a quarterly revenue of $150.04 million, exceeding expectations, and an EPS of ($0.92), surpassing the consensus estimate of ($1.00). Analysts have upgraded ratings, with target prices ranging from $150.00 to $190.00, and the average rating is 'Buy' with a consensus target price of $178.00. Key institutional investors including Principal Financial Group, Penserra Capital, UBS AM, Trek Financial, and Edgestream Partners adjusted their holdings. Hedge funds collectively own 81.49% of the company's stock. The company has a market cap of $5.46 billion, a negative P/E ratio of -21.58, and operates in biopharmaceuticals with products for CNS disorders such as Auvelity and Sunosi. Insiders, including COO Mark L. Jacobson and a director, have sold significant shares over the past ninety days, reducing their ownership by 22.30% of the total stock.